Multiple Myeloma | Specialty

Dr. Anderson on How the Definition of Myeloma Has Changed

April 2nd 2016

Kenneth C. Anderson, MD, Giant of Cancer Care: Myeloma, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, discusses how the definition of myeloma has changed.

Plitidepsin Improves PFS in Advanced Myeloma

April 1st 2016

Adding plitidepsin (Aplidin) to dexamethasone reduced the risk of disease progression by 35% versus dexamethasone alone in patients with relapsed/refractory multiple myeloma enrolled in the phase III ADMYRE trial.

Daratumumab Triplet Delays Progression in Multiple Myeloma

March 30th 2016

Adding daratumumab (Darzalex) to standard bortezomib (Velcade) and dexamethasone improved progression-free survival in patients with relapsed/refractory multiple myeloma enrolled in the phase III CASTOR (MMY3004) trial.

Dr. Branagan on Vaccine to Better Protect Myeloma Patients From Flu

March 29th 2016

Andrew R. Branagan, MD, postdoctoral associate in Medicine (Hematology), Yale Cancer Center, discusses the significance of a vaccine developed to better protect patients with multiple myeloma from getting the flu.

The Future of Immunotherapy in Myeloma

March 29th 2016

On the Horizon for Multiple Myeloma

March 29th 2016

Antibodies in Combination Therapy for Myeloma

March 29th 2016

Immunotherapy Patient Selection in Myeloma

March 29th 2016

Goals of Therapy in Multiple Myeloma

March 29th 2016

Practical Advice on the Treatment of Multiple Myeloma

March 29th 2016

Safety and Efficacy of Elotuzumab in Multiple Myeloma

March 29th 2016

Safety and Efficacy of Daratumumab in Multiple Myeloma

March 29th 2016

Monoclonal Antibody Therapy in Myeloma

March 29th 2016

Rationale for Immunotherapy in Multiple Myeloma

March 29th 2016

Dr. Jagannath on Next-Generation Approaches in Multiple Myeloma

March 21st 2016

Sundar Jagannath, MD, professor of Medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses upcoming agents in multiple myeloma.

Frontline Therapy Rapidly Evolving for Multiple Myeloma

March 18th 2016

Shaji Kumar, MD, discusses how the phase III SWOG S0777 study, which investigated the combination of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone, significantly changed the frontline treatment paradigm for patients with multiple myeloma

FDA Approves New Melphalan Formulation in Myeloma

March 15th 2016

The FDA has approved Captisol-enabled melphalan (Evomela) as a high-dose conditioning treatment for use in patients with multiple myeloma prior to autologous stem cell transplantation, as well as for the palliative treatment of patients with myeloma for whom oral therapy is not appropriate.

Palbociclib Sensitizes Myeloma Cells to Immunomodulatory Drugs

March 3rd 2016

Selina Chen-Kiang, MD, discusses how CDK 4/6 inhibition sensitizes myeloma cells to IMiDs and the impact this can have on the treatment of patients with multiple myeloma.

Dr. Jagannath on Sequencing Therapies for Patients With Multiple Myeloma

March 2nd 2016

Sundar Jagannath, MD, director of the Multiple Myeloma Program, professor of Medicine (Hematology and Medical Oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses sequencing challenges with therapies for patients with multiple myeloma.

Combinations Show Early Promise in Multiple Myeloma

March 1st 2016

Craig Hofmeister, MD, discusses two clinical trials examining combination regimens in relapsed/refractory patients with multiple myeloma.